Akebia Therapeutics Inc. (NASDAQ: AKBA) Emerges As Guiding Light For Investors

Akebia Therapeutics Inc. (NASDAQ:AKBA) currently has a daily average trading volume of 5.18M but it saw 3592621 shares traded in last market. With a market cap of 247.33M USD, the company’s current market price of $1.18 came falling about -4.07 while comparing to the previous closing price of $1.23. In past 52 weeks, the stock remained buoying in the range of price level as high as $2.48 and as low as $0.78.

Taking a look at 20-day trading activity of Akebia Therapeutics Inc. (AKBA) gives us an average price of $1.3270, while its current price level is -52.42% below from 52-week high level whereas it is 51.26% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.5190 while that of 200 days or SMA-200 reads an average of $1.3221. A closer look into the stock’s movement over the week reveals that its volatility is standing at 13.17% during that period while stretching the period over a month that decreases to 7.74%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 37.32 which implies that the stock is in neutral territory.

The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the BTIG Research which resumed the stock as “Buy” in its note to investors issued on November 29, 2023, recommending a price target of $4 for it. H.C. Wainwright upgraded its recommendation for the stock as a “Buy” from “Neutral” on August 28, 2023 while assigning a price target of $3.75. Piper Sandler issued its recommendations for the stock as it upgraded the price target for the stock in the range of between $2 and $4.

Over the week, AKBA’s stock price is moving -15.71% down while it is -15.71% when we observe its performance for the past one month. Year-to-date it is -4.84% down and over the past year, the stock is showing an upside performance of 8.26%.

The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of -0.06 beaten by the consensus estimate of -0.02 for the same. In next quarter, company is expected to be making quarterly sales of $43.58M as analysts are expecting the sales for current fiscal year at $180.68M and seeing the company making $159.52M in sales next year. Moreover, analysts are in estimates of $49.51M for current-quarter revenue.

Currently, Akebia Therapeutics Inc.’s total number of outstanding shares is 194.58M. Company’s return on investment (ROI) stands at -67.22% and return on equity (ROE) at -554.87%. Stock’s beta reads 0.81. Stock has a price to sale or P/S ratio amounts to 1.32. Its return on asset (ROA) is -17.13% on average.